Phase II Study of Celecoxib with Cisplatin Plus Etoposide in Extensive-Stage Small Cell Lung Cancer

REFERENCES

• Greenlee R. T., Murray T., Bolden S., et al. Cancer statistics, 2000. CA Cancer J Clin 2000; 50: 7–33
   PubMed Web of Science ®Google Scholar
• Osterlind K., Ihde D. C., Ettinger D. S., et al. Staging and prognostic factors in small cell carcinoma of the lung. Cancer Treat Rep 1983; 67: 3–9
   PubMedGoogle Scholar
• Aisner J. Extensive-disease small cell lung cancer: the thrill of victory; the agony of defeat. J Clin Oncol 1996; 14: 658–665
   PubMed Web of Science ®Google Scholar
• Roth B. J., Johnson D. H., Einhorn L. H., et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: phase III trial of Southeastern Cancer Study Group. J Clin Oncol 1992; 10: 282–291
   PubMed Web of Science ®Google Scholar
• Fukuoka M., Furuse K., Saijo N., et al. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these two regimens in small-cell lung cancer. J Natl Cancer Inst 1991; 83: 855–861
   PubMed Web of Science ®Google Scholar
• Bozcuk H., Artac M., Ozdogan M., et al. Does maintenance/consolidation chemotherapy have a role in the management of small cell lung cancer (SCLC)? A meta-analysis of the published randomized controlled trials. Cancer 2005; 104: 2650–2657
   PubMed Web of Science ®Google Scholar
• Kellof G. J., Steele V. E., Sigman C. C. Chemoprevention of cancer by NSAIDs and selective COX-2 blockade. COX-2 Blockade in Cancer Prevention and Therapy, R. E. Harris. Humana Press, New JerseyUSA 2003; 279–300
   Google Scholar
• Mitchell J. A., Akarasereenont P., Thiernermann C., et al. Selectivity of nonsteroidal anti-inflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA 1994; 90: 11693–11697
   Web of Science ®Google Scholar
• Vane J. R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature (New Biol) 1971; 231: 232–235
   PubMedGoogle Scholar
• O'Neil G. P., Ford-Hutchison A. W. Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett 1993; 330: 156–160
   PubMed Web of Science ®Google Scholar
• Smith W. L., Meade E. A., DeWitt D. L. Pharmacology of prostaglandin endoperoxide synthase isozymes 1 and 2. Ann NY Acad Sci 1994; 14: 136–142
   Google Scholar
• Markowitz S. D. Aspirin and colon cancer. N Engl J Med 2007; 356: 2195–2198
   PubMed Web of Science ®Google Scholar
• Chute J. P., Chen T., Feigal E., et al. Twenty years of phase III trials for patients with extensive-stage small cell lung cancer: perceptible progress. J Clin Oncol 1999; 17: 1794–1801
   PubMed Web of Science ®Google Scholar
• Wolff H., Saukkonen K., Anttila S., et al. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 1998; 58: 4997–5001
   PubMed Web of Science ®Google Scholar
• Subbaramaiah K., Zakin D., Dannenberg A. Inhibition of cyclooxygenase; a novel approach to cancer prevention. Exp Biol Med 1997; 216: 201–210
   PubMed Web of Science ®Google Scholar
• Graul A., Martel A. M., Castanar J. Celecoxib. Drugs Future 1999; 22: 711–714
   Google Scholar
• Soslow R. A., Dannenberg A. J., Rush D., et al. COX-2 is expressed in human colonic and mammary tumours. Cancer 2000; 89: 2637–2645
   PubMed Web of Science ®Google Scholar
• Alshafie G. A., Abou Issa H. M., Seibert K., et al. Chemotherapeutic evaluation of celecoxib, a cyclooxygenase-2 inihbitor, in a rat mammary tumour model. Oncol Rep 2000; 7: 1377–1381
   PubMed Web of Science ®Google Scholar
• Abou Issa H., Alshafie G. Celecoxib: a novel treatment for lung cancer. Exp Ver Anticancer Ther 2004; 4: 725–734
   PubMedGoogle Scholar
• Grosch S., Tegeder I., Niederberger E., et al. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J 2001; 15: 2742–2744
   PubMed Web of Science ®Google Scholar
• Xu X. C. COX-2 inhibitors in cancer treatment and prevention, a recent development. Anti-Cancer Drugs 2002; 13: 127–137
   PubMed Web of Science ®Google Scholar
• Frantz B., O'Neill E. A. The effect of sodium salicylate and aspirin on NF-kappa B. Science 1995; 270: 2017–2019
   PubMed Web of Science ®Google Scholar
• Huang C., Ma W. Y., Hanenberger D., et al. Inhibition of ultraviolet B–induced activator protein-1 (AP-1) activity by aspirin in AP-1-luciferase transgenic mice. J Biol Chem 1997; 272: 26325–26331
   PubMed Web of Science ®Google Scholar
• He T. C., Chan T. A., Vogelstein B., et al. PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 1999; 99: 335–345
   PubMed Web of Science ®Google Scholar
• Wick M., Hurteau G., Dessev C., et al. Peroxisome proliferator-activated receptor-gamma is a target of nonsteroidal anti-inflammatory drugs mediating cyclooxygenase-independent inhibition of lung cancer cell growth. Mol Pharmacol 2002; 62: 1207–1214
   PubMed Web of Science ®Google Scholar
• Cao Y., Pearman A. T., Zimmerman G. A., et al. Intracellular unesterefied arachidonic acid signals apoptosis. Proc Natl Acad Sci USA 2000; 97: 11280–11285
   PubMed Web of Science ®Google Scholar
• Sanchez-Alcazar J. A., Bradbury D. A., Pang, et al. Cyclooxygenase (COX) inhibitors induce apoptosis in non-small-cell lung cancer through cyclooxygenase-independent pathways. Lung Cancer 2003; 40: 33–44
   PubMed Web of Science ®Google Scholar
• Aaronson N. K., Ahmedzai S., Bergmam B., et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365–376
   PubMed Web of Science ®Google Scholar
• Bergmam B., Aaronson N. K., Ahmedzai S., et al. The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials—EORTC Study Group on Quality of Life. Eur J Cancer 1994; 30A: 635–642
   PubMed Web of Science ®Google Scholar
• Kaasa S., Bjordal K., Aaronson N. K., et al. The EORTC core quality of life questionnaire (QLQ-C30): validity and reliability when analysed with patients treated with palliative radiotherapy. Eur J Cancer 1995; 31A: 2260–2263
   PubMed Web of Science ®Google Scholar
• Bergmam B., Sullivan S., Sørenson S. Quality of life during chemotherapy for small cell lung cancer: a longitudinal study of the EORTC Core Quality of Life Questionnaire and comparison with the Sickness Impact Profile. Acta Oncol 1992; 31: 19–28
   PubMed Web of Science ®Google Scholar
• Fleming T. R. One sample multiple testing procedure for phase II clinical trials. Biometrics 1982; 38: 143–151
   PubMed Web of Science ®Google Scholar
• Fitzgerald G. A. Coxibs and cardiovascular disease. N Engl J Med 2004; 351: 1709–1711
   PubMed Web of Science ®Google Scholar
• Solomon D. S., McMurray J.J. V., Pfeffer M. A., et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 352: 1071–1080
   PubMed Web of Science ®Google Scholar
• Kerr D. J., Dunn J. A., Langman M. J., et al. Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer. N Engl J Med 2007; 357: 360–369
   PubMed Web of Science ®Google Scholar
• Hesketh P. J., Chansky K., Israel V., et al. Phase II study of gemcitabine and cisplatin in patients with previously untreated extensive stage small cell lung cancer: Southwest Oncology Group Study 9718. J Thorac Oncol 2007; 2: 440–444
   PubMed Web of Science ®Google Scholar
• De Marinis F., Nelli F., Lombardo M., et al. A multicenter, randomized, phase II study of cisplatin, etoposide, and gemcitabine or cisplatin plus gemcitabine as first-line treatment in patients with poor-prognosis small cell lung carcinoma. Cancer 2005; 103: 772–779
   PubMed Web of Science ®Google Scholar
• Johnson D., Csiki I., Gonzalez A., et al. Cyclooxygenase-2 (COX-2) inhibition in non-small-cell lung cancer (NSCLC): preliminary results of a phase II trial. Proc Am Soc Clin Oncol 2003; 22: 640, Abstr. 2575
   Google Scholar
• Edleman M. J., Watson D. M., Wang X., et al. Eicosanoid modulation in advanced non-small-cell lung cancer (NSCLC): CALGB 30203. J Clin Oncol 2006; 24: 370s, Suppl. Abstr. 7025
   PubMed Web of Science ®Google Scholar
• Reckamp K. L., Krysan K., Morrow J. D., et al. A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small-cell lung cancer. Clin Cancer Res 2006; 12: 3381–3388
   PubMed Web of Science ®Google Scholar
• Csiki I., Johnson D. Did targeted therapy fail cyclooxygenase too?. J Clin Oncol 2006; 24: 4798–4800
   PubMed Web of Science ®Google Scholar